Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced the oral presentation’s acceptance and information at the American College of Rheumatology Convergence 2021.
Tonix’s oral presentation was accepted at ACR Convergence 2021
The ACR Convergence 2021 will virtually take place between November 5, 2021, and November 9, 2021. The title of the presentation is “TNX-102 SL (Sublingual Cyclobenzaprine) for the Treatment of Fibromyalgia in the RELIEF Study: Positive Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Trial.”
Tonix focuses on discovering, acquiring, licensing, and developing small biologics and molecules to prevent and treat human diseases. Its portfolio includes central nervous system and immunology product candidates. The immunological portfolio includes COVID-19 product candidates preventing and treating COVID-19.
The company’s lead COVID-19 candidate TNX-1800 elicits a T-cell response, and in Q1 2021, Tonix reported positive efficacy findings from animal models. Human studies are expected to commence in 1H 2022.
Tonix expand its collaboration with Columbia University
Recently the company announced the expansion of its research partnership with Columbia University. The partnership is for studying COVID-19 immune responses in healthy subjects who have recovered from the virus or are asymptomatic and investigating in vitro antibody and cell responses to SARS-CoV-2. The research seeks to fill vital gaps in the understanding immune response to COVID-19 and offer a foundation for customizing therapeutics and vaccines.
CEO Seth Lederman said, “Based on the progress and results of the initial phase of these projects, we are excited to expand our research collaboration with Columbia University on these precision medicine technologies and also to potentially develop new monoclonal antibody therapeutics. Data from this collaboration may provide a roadmap and tools to potentially guide the selection of appropriate individuals for COVID-19 vaccine trials and to help determine which vaccine is appropriate for each individual based on the condition of their immune system or other physiological features.”
